Tekla Capital Management LLC Coherus Bio Sciences, Inc. Transaction History

Tekla Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$16.56 - $18.94 $3.36 Million - $3.85 Million	-203,103 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$14.43 - $19.16 $1.32 Million - $1.75 Million	91,440 Added 81.89%	203,103 $3.63 Million
Q1 2020 May 14, 2020	SELL	$11.67 - $22.53 $157,346 - $303,771	-13,483 Reduced 10.77%	111,663 $1.81 Million
Q4 2019 Feb 13, 2020	SELL	$16.33 - $21.37 $1.14 Million - $1.5 Million	-70,000 Reduced 35.87%	125,146 $2.25 Million
Q3 2019 Nov 13, 2019	SELL	$16.3 - $23.37 $1.57 Million - $2.25 Million	-96,273 Reduced 33.04%	195,146 $3.95 Million
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $311,033 - $524,720	-23,743 Reduced 7.53%	291,419 $6.44 Million
Q4 2018 Feb 13, 2019	BUY	$8.65 - $16.28 $1.43 Million - $2.69 Million	165,342 Added 110.36%	315,162 $2.85 Million
Q3 2018 Nov 13, 2018	SELL	$14.45 - $20.25 $1.32 Million - $1.84 Million	-91,023 Reduced 37.79%	149,820 $2.47 Million
Q2 2018 Aug 13, 2018	BUY	$10.25 - $17.45 $613,155 - $1.04 Million	59,820 Added 33.05%	240,843 $3.37 Million
Q1 2018 May 14, 2018	BUY	$9.1 - $13.7 $828,309 - $1.25 Million	91,023 Added 101.14%	181,023 $2 Million
Q2 2017 Aug 14, 2017	BUY	N/A	90,000	90,000 $1.29 Million

130

67.8M

1.68M

91.8K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $69.2M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.